Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prasterone, also known as dehydroepiandrosterone (DHEA), is a synthetic small molecule steroid and an endogenous hormone precursor produced by the adrenal glands. It serves as an inactive metabolic intermediate that undergoes intracellular conversion into active androgens and estrogens, such as testosterone and estradiol, via tissue-specific steroidogenic enzymes. This mechanism, termed intracrinology, allows for localized hormonal action with minimal systemic impact. Marketed under the brand name Intrarosa as an intravaginal insert, prasterone is FDA-approved for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy associated with menopause. Beyond its approved use, DHEA is widely available as a dietary supplement and has been investigated for various conditions, including adrenal insufficiency, systemic lupus erythematosus, and potential lipid-lowering effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prasterone.